Objectives To describe the treatment patterns and outcomes of Chinese non-small cell lung
cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion
(ex20ins) mutations in real-world as EGFR ex20ins consist of a diverse group of mutations
with limited information on the clinical outcome of these patients treated with chemotherapy
or EGFR tyrosine kinase inhibitors (TKIs). Materials and methods Real-world treatment
outcomes of Chinese NSCLC patients harboring EGFR ex20ins were retrospectively …

Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development
of EGFR tyrosine kinase inhibitors (TKIs) marked the beginning of the targeted therapy era
for non-small-cell lung cancer (NSCLC). Thirty percent of NSCLC patients carry EGFR gene
mutations. For these advanced NSCLC patients, EGFR-TKIs are currently preferred for their
superior activity and survival benefits over platinum-based chemotherapy. However …